Café

© 2026 Longbridge｜Terms of Service Privacy Policy

PALI

PALI

1.9700.51%( +0.010 )

LongbridgeAI

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Unusual Whales

Aug 10, 2026 at 08:21 PM

Progressing a novel once-daily oral prodrug PDE4 inhibitor, optimized for local activation, to potentially become a top choice for treating inflammatory bowel disease (IBD).

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Palisade Bio

PALI.US

Open

--

High

--

Low

--

Prev Close

--

P/E^TTM

--

Market Cap

--